Over the past decades, there have been great advancements in the antithrombotic management of patients undergoing percutaneous interventions, but most of the available evidence derives from studies conducted in the setting of cardiac interventions. Antithrombotic treatment regimens used in patients undergoing percutaneous cardiac interventions, in particular coronary, are frequently extrapolated to patients undergoing noncardiac interventions. However, the differences in risk profile of the population treated and the types of interventions performed may translate into differences is the safety and efficacy associated with antithrombotic therapy. Noncardiac percutaneous interventions are commonly performed in patients at high bleeding risk, which may indeed impact outcomes, hence underscoring the importance of risk stratification to guide clinical decision-making processes. In this review, we appraise the available evidence on antithrombotic therapy in high-bleeding-risk patients undergoing noncardiac percutaneous interventions.

中文翻译：

---

高出血风险的抗血栓治疗，第二部分：非心脏经皮介入治疗。


在过去的几十年里，接受经皮介入治疗的患者的抗血栓治疗取得了巨大进步，但大多数可用证据来自在心脏介入治疗的情况下进行的研究。接受经皮心脏介入治疗（尤其是冠状动脉介入治疗）的患者使用的抗血栓治疗方案通常外推到接受非心脏介入治疗的患者。然而，接受治疗的人群的风险状况和所进行的干预类型的差异可能转化为与抗血栓治疗相关的安全性和有效性的差异。非心脏经皮介入治疗通常在出血风险高的患者中进行，这确实可能影响结局，因此强调了风险分层对指导临床决策过程的重要性。在本综述中，我们评估了接受非心脏经皮介入治疗的高出血风险患者抗血栓治疗的现有证据。